多発性骨髄腫治療薬の世界市場レポート 2025年

多発性骨髄腫治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には299億9,000万米ドルに成長し、CAGRは6.6%となります。予測期間の成長は、免疫療法の革新、標的療法の拡大、リキッドバイオプシーの応用、car-t細胞療法の出現、バイオマーカーの発見などに起因すると考えられます。予測期間における主な動向には、長期生存率重視、エピジェネティック療法の探求、遠隔医療の役割拡大、新規治療へのアクセス拡大、骨髄腫治療の持続可能性などが含まれます。

多発性骨髄腫治療薬市場の予想成長は、血液がんの有病率の増加によって牽引されると予想されます。血液がんは、骨髄や免疫系細胞などの造血組織に発生し、白血病、リンパ腫、多発性骨髄腫などの疾患が含まれます。多発性骨髄腫治療薬は、がん細胞の増殖を抑制し、細胞分裂を抑え、様々な酵素活性を刺激し、骨の強度を高めることで骨の弱化に伴う痛みを和らげるなど、これらのがんの治療において重要な役割を果たしています。2023年1月現在、米国がん協会は、新たに白血病と診断された症例が約59,610例、急性骨髄性白血病（AML）が約20,380例、白血病に起因する死亡が23,710例であると報告しています。血液がんの罹患率の増加は、多発性骨髄腫治療薬に対する需要の高まりを裏付けています。

バイオテクノロジーと精密医療の進歩は、市場の成長に大きく貢献すると予想されます。革新的な製品を開発するための生物学的システムの応用を含むバイオテクノロジーと、遺伝学や分子プロファイルなどの個人の特性に合わせた個別化医療アプローチである精密医療は、多発性骨髄腫治療薬の活用に役立っています。これらの先端技術は、遺伝学的・分子生物学的知見を活用し、個々の患者に合った標的治療を特定することで、治療効果を最適化します。2022年10月現在、個別化医療連合（Personalized Medicine Coalition）の推計によると、様々ながん、遺伝性疾患、慢性疾患に対して、75,000を超える遺伝子検査キットと300を超える個別化治療が利用可能になるとされています。バイオテクノロジーと精密医療の継続的な進歩が、多発性骨髄腫治療薬市場拡大の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界多発性骨髄腫治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の多発性骨髄腫治療薬市場：成長率分析
• 世界の多発性骨髄腫治療薬市場の実績：規模と成長, 2019-2024
• 世界の多発性骨髄腫治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界多発性骨髄腫治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の多発性骨髄腫治療薬市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫調節薬
• プロテアソーム阻害剤
• ヒストン脱アセチル化酵素阻害剤
• モノクローナル抗体医薬品
• ステロイド
• その他の薬物の種類
• 世界の多発性骨髄腫治療薬市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的療法
• 生物学的療法
• 化学療法
• その他の治療法
• 世界の多発性骨髄腫治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の多発性骨髄腫治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 男性
• 女性
• 世界の多発性骨髄腫治療薬市場、免疫調節薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• レナリドミド
• サリドマイド
• ポマリドミド
• 世界の多発性骨髄腫治療薬市場プロテアソーム阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ボルテゾミブ
• カルフィルゾミブ
• イキサゾミブ
• 世界の多発性骨髄腫治療薬市場ヒストン脱アセチル化酵素阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• パノビノスタット
• ロミデプシン
• 世界の多発性骨髄腫治療薬市場モノクローナル抗体医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ダラツムマブ
• エロツズマブ
• イサツキシマブ
• 世界の多発性骨髄腫治療薬市場ステロイドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デキサメタゾン
• プレドニゾン
• 世界の多発性骨髄腫治療薬市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルキル化剤
• 代謝拮抗物質
• 新しい実験薬

第7章 地域別・国別分析

• 世界の多発性骨髄腫治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の多発性骨髄腫治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多発性骨髄腫治療薬市場：競合情勢
• 多発性骨髄腫治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Pvt. Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Roche Holding AG
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Kite Pharma Inc
• Amgen Inc.
• AstraZeneca plc
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Daiichi Sankyo Company
• Lonza Group AG
• Cipla Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 多発性骨髄腫治療薬市場2029：新たな機会を提供する国
• 多発性骨髄腫治療薬市場2029：新たな機会を提供するセグメント
• 多発性骨髄腫治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Multiple myeloma pharmaceuticals are medications designed for the treatment of multiple myeloma and related malignancies affecting plasma cells within the bone marrow. These therapeutic agents are specifically formulated to manage skeletal complications associated with myeloma, including pamidronate (Aredia) and zoledronic acid (Zometa).

Key therapeutic categories for multiple myeloma encompass immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors, monoclonal antibody therapies, corticosteroids, among others. Targeted therapy represents an innovative approach in oncology, leveraging drugs or compounds to directly engage essential molecular targets pivotal for cancer cell viability and growth. In the context of multiple myeloma, these treatments are tailored to engage specific molecules, such as intracellular proteins, which modulate cellular signaling pathways promoting proliferation. Various therapeutic modalities include targeted therapy, biologic interventions, chemotherapy, among others, with diverse distribution channels encompassing hospital-based pharmacies, community retail pharmacies, online pharmaceutical platforms, and other avenues, catering to both male and female patient demographics.

The multiple myeloma drugs market research report is one of a series of new reports from The Business Research Company that provides multiple myeloma drugs market statistics, including multiple myeloma drugs industry global market size, regional shares, competitors with a multiple myeloma drugs market share, detailed multiple myeloma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple myeloma drugs industry. This multiple myeloma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The multiple myeloma drugs market size has grown strongly in recent years. It will grow from $21.84 billion in 2024 to $23.25 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to improved diagnosis, clinical trials success, understanding of disease biology, healthcare infrastructure improvements, patient advocacy, and awareness

The multiple myeloma drugs market size is expected to see strong growth in the next few years. It will grow to $29.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to immunotherapy innovations, targeted therapies expansion, liquid biopsy applications, the emergence of car-t cell therapy, and biomarker discovery. Major trends in the forecast period include long-term survivorship focus, exploration of epigenetic therapies, expanded role of telemedicine, expanded access to novel therapies, and sustainability in myeloma care.

The anticipated growth of the multiple myeloma drugs market is expected to be driven by the increasing prevalence of hematological cancer. Hematological cancers, originating in blood-forming tissues such as bone marrow or immune system cells, include conditions such as leukemia, lymphoma, multiple myeloma, among others. Multiple myeloma medications play a crucial role in treating these cancers by inhibiting the growth of cancer cells, reducing cell division, stimulating various enzymatic activities, and contributing to bone strength, thereby alleviating pain associated with bone weakening. As of January 2023, the American Cancer Society reported approximately 59,610 newly diagnosed cases of leukemia, with around 20,380 cases of acute myeloid leukemia (AML) and 23,710 deaths attributed to leukemia. The rising incidence of hematological cancer underscores the growing demand for multiple myeloma drugs.

The progress in biotechnology and precision medicine is expected to significantly contribute to the market's growth. Biotechnology, involving the application of biological systems to develop innovative products, and precision medicine, a personalized healthcare approach tailored to individual characteristics such as genetics and molecular profile, are instrumental in utilizing multiple myeloma drugs. These advanced technologies leverage genetic and molecular insights to identify targeted therapies personalized for individual patients, thereby optimizing treatment effectiveness. As of October 2022, estimates from the Personalized Medicine Coalition indicated that over 75,000 genetic testing kits and 300 personalized treatments would be available for various cancers, hereditary disorders, and chronic diseases. The continued advancement in biotechnology and precision medicine is a driving force behind the expansion of the multiple myeloma drugs market.

Product innovation is a key trend gaining popularity in the multiple myeloma drugs market. Major companies operating in the multiple myeloma drugs market are focused on developing innovative products to strengthen their Product innovation emerges as a prominent trend shaping the landscape of the multiple myeloma drugs market, with major industry players prioritizing the development of novel products to enhance their market standing and gain a competitive edge. A case in point is Janssen Biotech Inc., a Japanese biotechnology company, which secured approval from the United States Food and Drug Administration in March 2022 for Carvykti, a CAR T-Cell therapy designed for multiple myeloma treatment. Carvykti, utilizing genetically modified autologous T cells, features a chimeric antigen receptor (CAR) targeting B cell maturation antigen (BCMA). Eligible patients, having undergone multiple lines of therapy, including essential myeloma medications, can receive this therapy for the management of relapsed conditions.

Strategic partnerships represent another key approach adopted by major companies in the multiple myeloma drugs market to collaboratively develop and commercialize innovative products. An exemplar is the collaboration between Kite Pharma, a subsidiary of Gilead Sciences Inc., a US-based pharmaceutical company, and Arcellx, a US-based biotechnology company. Their partnership, established in December 2022, focuses on the joint development and commercialization of Arcellx's T-cell therapy, CART-ddBCMA, targeting relapsed or refractory multiple myeloma patients. This therapy incorporates Arcellx's unique D-Domain binder and involves autologous T cells genetically modified for effective multiple myeloma targeting.

In August 2022, Ipsen, a France-based biopharmaceutical company, acquired Epizyme, Inc. for an undisclosed amount. The acquisition aims to strengthen Ipsen's oncology portfolio by incorporating Epizyme's innovative therapies. This strategic move enables Ipsen to utilize its established infrastructure and scientific expertise to provide cutting-edge treatment options to underserved patients. Epizyme, Inc., a U.S.-based biotechnology company, specializes in manufacturing drugs for multiple myeloma.

Major companies operating in the multiple myeloma drugs market include Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB

North America was the largest region in the multiple myeloma drugs market in 2024. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multiple myeloma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multiple myeloma drugs market consists of revenues earned by entities by providing various therapies such radiation therapy, bone-marrow transplant, surgery and stem-cell transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiple myeloma drug market also includes sales of nuclear export inhibitors, bispecific T cell engager (BiTE), bisphosphonates, and alkylating agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multiple Myeloma Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multiple myeloma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multiple myeloma drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multiple myeloma drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Immunomodulatory Drugs; Proteasome Inhibitors; Histone Deacetylase Inhibitors; Monoclonal Antibody Drugs; Steroids; Other Drug Types
• 2) By Therapy: Targeted Therapy; Biologic Therapy; Chemotherapy; Other Therapies
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 4) By End-User: Men; Women
• Subsegments:
• 1) By Immunomodulatory Drugs: Lenalidomide; Thalidomide; Pomalidomide
• 2) By Proteasome Inhibitors: Bortezomib; Carfilzomib; Ixazomib
• 3) By Histone Deacetylase Inhibitors: Panobinostat; Romidepsin
• 4) By Monoclonal Antibody Drugs: Daratumumab; Elotuzumab; Isatuximab
• 5) By Steroids: Dexamethasone; Prednisone
• 6) By Other Drug Types: Alkylating Agents; Antimetabolites; New Experimental Drugs
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Pvt. Ltd; Merck & Co. Inc.; AbbVie Inc.; Bayer AG.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multiple Myeloma Drugs Market Characteristics

3. Multiple Myeloma Drugs Market Trends And Strategies

4. Multiple Myeloma Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Multiple Myeloma Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Multiple Myeloma Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Multiple Myeloma Drugs Market Growth Rate Analysis
• 5.4. Global Multiple Myeloma Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Multiple Myeloma Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Multiple Myeloma Drugs Total Addressable Market (TAM)

6. Multiple Myeloma Drugs Market Segmentation

• 6.1. Global Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunomodulatory Drugs
• Proteasome Inhibitors
• Histone Deacetylase Inhibitors
• Monoclonal Antibody Drugs
• Steroids
• Other Drug Types
• 6.2. Global Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Biologic Therapy
• Chemotherapy
• Other Therapies
• 6.3. Global Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Men
• Women
• 6.5. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Immunomodulatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lenalidomide
• Thalidomide
• Pomalidomide
• 6.6. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Proteasome Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bortezomib
• Carfilzomib
• Ixazomib
• 6.7. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Histone Deacetylase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Panobinostat
• Romidepsin
• 6.8. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Monoclonal Antibody Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Daratumumab
• Elotuzumab
• Isatuximab
• 6.9. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dexamethasone
• Prednisone
• 6.10. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alkylating Agents
• Antimetabolites
• New Experimental Drugs

7. Multiple Myeloma Drugs Market Regional And Country Analysis

• 7.1. Global Multiple Myeloma Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Multiple Myeloma Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multiple Myeloma Drugs Market

• 8.1. Asia-Pacific Multiple Myeloma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multiple Myeloma Drugs Market

• 9.1. China Multiple Myeloma Drugs Market Overview
• 9.2. China Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multiple Myeloma Drugs Market

• 10.1. India Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multiple Myeloma Drugs Market

• 11.1. Japan Multiple Myeloma Drugs Market Overview
• 11.2. Japan Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multiple Myeloma Drugs Market

• 12.1. Australia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multiple Myeloma Drugs Market

• 13.1. Indonesia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multiple Myeloma Drugs Market

• 14.1. South Korea Multiple Myeloma Drugs Market Overview
• 14.2. South Korea Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multiple Myeloma Drugs Market

• 15.1. Western Europe Multiple Myeloma Drugs Market Overview
• 15.2. Western Europe Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multiple Myeloma Drugs Market

• 16.1. UK Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multiple Myeloma Drugs Market

• 17.1. Germany Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multiple Myeloma Drugs Market

• 18.1. France Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multiple Myeloma Drugs Market

• 19.1. Italy Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multiple Myeloma Drugs Market

• 20.1. Spain Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multiple Myeloma Drugs Market

• 21.1. Eastern Europe Multiple Myeloma Drugs Market Overview
• 21.2. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multiple Myeloma Drugs Market

• 22.1. Russia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multiple Myeloma Drugs Market

• 23.1. North America Multiple Myeloma Drugs Market Overview
• 23.2. North America Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multiple Myeloma Drugs Market

• 24.1. USA Multiple Myeloma Drugs Market Overview
• 24.2. USA Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multiple Myeloma Drugs Market

• 25.1. Canada Multiple Myeloma Drugs Market Overview
• 25.2. Canada Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multiple Myeloma Drugs Market

• 26.1. South America Multiple Myeloma Drugs Market Overview
• 26.2. South America Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multiple Myeloma Drugs Market

• 27.1. Brazil Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multiple Myeloma Drugs Market

• 28.1. Middle East Multiple Myeloma Drugs Market Overview
• 28.2. Middle East Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multiple Myeloma Drugs Market

• 29.1. Africa Multiple Myeloma Drugs Market Overview
• 29.2. Africa Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multiple Myeloma Drugs Market Competitive Landscape And Company Profiles

• 30.1. Multiple Myeloma Drugs Market Competitive Landscape
• 30.2. Multiple Myeloma Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Pvt. Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG. Overview, Products and Services, Strategy and Financial Analysis

31. Multiple Myeloma Drugs Market Other Major And Innovative Companies

• 31.1. Roche Holding AG
• 31.2. Novartis AG
• 31.3. Sanofi S.A.
• 31.4. Bristol-Myers Squibb Company
• 31.5. GlaxoSmithKline Plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Kite Pharma Inc
• 31.9. Amgen Inc.
• 31.10. AstraZeneca plc
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Regeneron Pharmaceuticals Inc.
• 31.13. Daiichi Sankyo Company
• 31.14. Lonza Group AG
• 31.15. Cipla Ltd.

32. Global Multiple Myeloma Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multiple Myeloma Drugs Market

34. Recent Developments In The Multiple Myeloma Drugs Market

35. Multiple Myeloma Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Multiple Myeloma Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Multiple Myeloma Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Multiple Myeloma Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer